Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
1
Clinical Genomics and Pharmacogenomics Unit, 4th Department of Internal Medicine, “Attikon” Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
2
Molecular Biology Division, Biomedical Research Foundation of the Academy of Athens, 11527 Athens, Greece
3
Department of Biochemistry, University of Crete, Medical School, 71003 Heraklion, Greece
4
Center for New Biotechnologies and Precision Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2018, 8(4), 34; https://doi.org/10.3390/jpm8040034
Received: 3 August 2018
/
Revised: 26 September 2018
/
Accepted: 27 September 2018
/
Published: 3 October 2018
(This article belongs to the Special Issue Personalized and Targeted Atherosclerosis Treatments)
Atherosclerosis affects millions of people worldwide. However, the wide variety of limitations in the current therapeutic options leaves much to be desired in future lipid-lowering therapies. For example, although statins, which are the first-line treatment for coronary heart disease (CHD), reduce the risk of cardiovascular events in a large percentage of patients, they lead to optimal levels of low density lipoprotein-cholesterol (LDL-C) in only about one-third of patients. A new promising research direction against atherosclerosis aims to improve lipoprotein metabolism. Novel therapeutic approaches are being developed to increase the levels of functional high density lipoprotein (HDL) particles. This review aims to highlight the atheroprotective potential of the in vitro synthesized reconstituted HDL particles containing apolipoprotein E (apoE) as their sole apolipoprotein component (rHDL-apoE). For this purpose, we provide: (1) a summary of the atheroprotective properties of native plasma HDL and its apolipoprotein components, apolipoprotein A-I (apoA-I) and apoE; (2) an overview of the anti-atherogenic functions of rHDL-apoA-I and apoA-I-containing HDL, i.e., natural HDL isolated from transgenic Apoa1−/− × Apoe−/− mice overexpressing human apoA-I (HDL-apoA-I); and (3) the latest developments and therapeutic potential of HDL-apoE and rHDL-apoE. Novel rHDL formulations containing apoE could possibly present enhanced biological functions, leading to improved therapeutic efficacy against atherosclerosis.
View Full-Text
Keywords:
atherosclerosis; lipoprotein metabolism; reconstituted HDL; apolipoprotein A-I; apolipoprotein E
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
MDPI and ACS Style
Valanti, E.-K.; Dalakoura-Karagkouni, K.; Sanoudou, D. Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis. J. Pers. Med. 2018, 8, 34. https://doi.org/10.3390/jpm8040034
AMA Style
Valanti E-K, Dalakoura-Karagkouni K, Sanoudou D. Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis. Journal of Personalized Medicine. 2018; 8(4):34. https://doi.org/10.3390/jpm8040034
Chicago/Turabian StyleValanti, Eftaxia-Konstantina, Katerina Dalakoura-Karagkouni, and Despina Sanoudou. 2018. "Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis" Journal of Personalized Medicine 8, no. 4: 34. https://doi.org/10.3390/jpm8040034
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
